NaF and FDG PET/CT in Detection of Occult Metastatic Disease in Recurrence of Prostate Cancer

H Jadvar, B Desai, L Ji, P.S. Conti, T.B. Dorff, S.G. Groshen, M.E. Gross, J.K. Pinski and D.I. Quinn |  2012-07-01

18F NaF and 18F FDG PET/CT were evaluated for their ability to detect occult metastatic disease in cases of prostate cancer relapse. Study shows that 18F NaF is useful in detecting occult osseous metastases, whereas the 18F FDG yield is more limited.

*SODIUM FLUORIDE F 18 INJECTION
For Intravenous Use

 

INDICATIONS AND USAGE
Sodium Fluoride F 18 Injection is a radioactive diagnostic agent for positron emission tomography (PET) indicated for imaging of bone to define areas of altered osteogenic activity.

 

IMPORTANT SAFETY INFORMATION

Allergic Reactions: As with any injectable drug, allergic reactions and anaphylaxis may occur. Emergency resuscitation equipment and personnel should be immediately available.

 

Cancer Risk: Sodium fluoride F18 injection may increase the risk of cancer. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker.

 

Adverse Reactions: No adverse reactions have been reported for Sodium Fluoride F 18 based on a review of the published literature, publicly available reference sources, and adverse drug reaction reporting systems.

 

Siemens' PETNET Solutions is a manufacturer of Sodium Fluoride F 18 Injection (18F NaF). Indication and important safety information as approved by the US Food and Drug Administration can be found at the links below for sodium fluoride 18F NaF, adult dose 8-12 mCi, administered by intravenous injection.

*FLUDEOXYGLUCOSE F 18 INJECTION

For Intravenous Use

 

INDICATIONS AND USAGE
Fludeoxyglucose F 18 injection (18F FDG) is indicated for positron emission tomography (PET) imaging in the following settings:

 

Oncology: For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer.

 

Cardiology: For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging.

 

Neurology: For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures.

 

IMPORTANT SAFETY INFORMATION
Radiation Risks: Radiation-emitting products, including fludeoxyglucose F 18 injection, may increase the risk for cancer, especially in pediatric patients. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker.

 

Blood Glucose Abnormalities: In the oncology and neurology setting, suboptimal imaging may occur in patients with inadequately regulated blood glucose levels. In these patients, consider medical therapy and laboratory testing to assure at least two days of normoglycemia prior to fludeoxyglucose F18 injection administration.

 

Adverse Reactions: Hypersensitivity reactions with pruritus, edema and rash have been reported; have emergency resuscitation equipment and personnel immediately available.

 

Siemens' PETNET Solutions is a manufacturer of Fludeoxyglucose F18 Injection (18F FDG). Indication and important safety information as approved by the US Food and Drug Administration can be found at the links below for 18F FDG, adult dose 5-10 mCi, administered by intravenous injection.

Related Articles